Welcome to NLS Pharma

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.


Our multidisciplinary Team, led by professionals with a long track record in drug development and management, relies on highly skilled personnel with unique competence in developing integrated solutions.

Latest News

  • Mar 18, 2018
    A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
  • Feb 5, 2018
    NLS Presents Positive Phase 2 Study Results for Mazindol at APSARD
  • Oct 31, 2017
    NLS Pharma Announces Poster Presentation On Efficacy and Safety Data of a Controlled Release (CR) Formulation of Mazindol in Adults with ADHD at AACAP’s & APSARD’s Annual Meeting
  • May 31, 2017
    NLS Pharma unveils positive phase 2 data for NLS-1 (Mazindol CR) in adults with ADHD, demonstrating significant improvement in symptoms
Contact us

NLS Pharma is very interested in hearing from you. Please find general contact information below.

Alter Postplatz 2
CH-6370 Stans NW

T: +41 41 618 80 00
F: +41 41 618 80 09

Your Name (required)

Your Email (required)


Your Message